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Abstract
BK polyomavirus (BKPyV) reactivation in kidney transplant recipients can lead to allograft
damage and loss. The elements of the adaptive immune system that are permissive of reac-
tivation and responsible for viral control remain incompletely described. We performed a
prospective study evaluating BKPyV-specific T-cell response, humoral response and overall
T-cell phenotype beginning pre-transplant through one year post-transplant in 28 patients at
two centers. We performed an exploratory analysis of risk factors for the development of
viremia and viruria as well as compared the immune response to BKPyV in these groups
and those who remained BK negative. 6 patients developed viruria and 3 developed viremia.
BKPyV-specific CD8+ T-cells increased post-transplant in viremic and viruric but not BK
negative patients. BKPyV-specific CD4+ T-cells increased in viremic, but not viruric or BK
negative patients. Anti-BKPyV IgG antibodies increased in viruric and viremic patients but
remained unchanged in BK negative patients. Viremic patients had a greater proportion of
CD8+ effector cells pre-transplant and at 12 months post-transplant. Viremic patients had
fewer CD4+ effector memory cells at 3 months post-transplant. Exploratory analysis demon-
strated lower CD4 and higher total CD8 proportions, higher anti-BKPyV antibody titers and
the cause of renal failure were associated BKPyV reactivation. In conclusion, low CD4, high
CD8 and increased effector CD8 cells were found pre-transplant in patients who became
viremic, a phenotype associated with immune senescence. This pre-transplant T-cell
senescence phenotype could potentially be used to identify patients at increased risk of
BKPyV reactivation.
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Introduction
BK polyomavirus (BKPyV) is a human polyomavirus first isolated in 1971 from a kidney trans-
plant recipient (KTR) with ureteral stenosis [1]. The virus persists latently in the renal and uri-
nary epithelium [2]. In KTRs viral reactivation can lead to ureteral stricture or an interstitial
nephritis termed BK Polyomavirus nephropathy (BKN)[3, 4]. BKPyV reactivation in blood
(viremia) is detected in up to 50% of KTRs with BKN occurring in approximately 10% [5, 6].
BKN is associated with high rates of graft loss [7–11], and viremia is associated with acute
rejection, declining allograft function [11] and the development of de novo donor specific anti-
bodies [12].
Currently, it is recommended that all KTRs be screened for BKPyV by PCR of urine or
blood post-transplant [8, 13]. The only treatment known to be efficacious is reduction in
immune suppression (IS)[14], which carries with it the risk of acute rejection [15]. Previous
studies have demonstrated low or negative anti-BKPyV antibodies [16, 17] and low or absent
BKPyV-specific T-cells prior to transplant [8, 18, 19] are risk factors for BKPyV reactivation.
The development of BKPyV-specific T-cells without IS reduction has been associated with
self-limited viremia, and failure to develop BKPyV-specific cellular response is associated with
prolonged viremia and BKN [20, 21]. Rising anti-BKPyV IgG and IgM antibody titers are asso-
ciated with viral reactivation and correlate with severity of disease [22–25].
Although previous studies have evaluated the BKPyV-specific T-cell response, detailed lon-
gitudinal understanding of such response in context of clinical characteristics and outcomes is
lacking. Furthermore, no studies have attempted to evaluate pre-transplant T-cell phenotypes
in order to establish whether specific profiles may alter reactivation risk. We hypothesized that
risk of developing BKV-associated diseases post-transplant may in part be determined by spe-
cific immune factors pre-transplant. In this exploratory study, we prospectively followed 28
patients who underwent renal transplantation at two local institutions. We assessed the pres-
ence of BKPyV-specific humoral and cellular immune response before transplant and for one
year post-transplant to identify early BKPyV-specific immune alterations to identify those
who were protected against BKPyV viremia or reactivation limited to the urine (viruria). Addi-
tionally, we performed an immuno-phenotype analysis of T-cells to identify pre-transplant
phenotypic alterations which may be permissive of or protective against viral reactivation.
Methods
Subjects and sample collection
This prospective observational cohort study was approved by the internal review boards of
Beth Israel Deaconess Medical Center and the Brigham and Women’s Hospital. Patients were
enrolled at the transplant clinics of both institutions from September 2012 to October 2014.
Urine and peripheral blood samples were collected before kidney transplantation and 1, 3, 6
and 12 months post-transplant. Plasma and peripheral blood mononuclear cells (PBMC) were
isolated and aliquots of PBMC, plasma and urine were stored at -80˚C. Demographic and clin-
ical information, including BKPyV urine and serum PCR screening values, were collected
from the medical record.
Intracellular cytokine staining (ICS)
PBMC were separated by Ficoll-Paque gradient centrifugation, washed, and resuspended in
RPMI-1640 with 12% fetal calf serum media to a concentration of 3.5 × 106 cells/ml. PBMC
(7 × 106) were plated without peptides to serve as the negative control, or stimulated with
BKPyV VP1 peptide pool of 15mers overlapping by 11, covering the entire VP1 capsid (JPT,
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Germany), at a final concentration of 2μg/mL. Cells were cultured for 10–14 days; after the
first 96 hours, the medium was supplemented with 25 U/ml interleukin-2 (IL-2). After this
time, 1x106 lymphocytes were washed twice to remove IL-2, and plated in RPMI 1640 with
12%FBS (negative control), with BKPyV peptide pool (2μg/mL), or PMA (1μg/μL) and Iono-
mycin (5μg/μL) as positive control, at 37˚C for 6 hours. After the first hour, all cells received
monensin (GolgiStop; BD Biosciences).
Cells were stained with fluorescently-conjugated antibodies specific for human CD4 (clone
L200) and CD8 (clone SK1). They were then permeabilized, stained for IFN-γ (clone B27) and
CD3 (clone SP34.2), and finally fixed. All antibodies were obtained from BD Biosciences. Data
were collected using a LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo soft-
ware (Treestar Inc.). ICS results were considered positive if the percentage of IFN- γ producing
CD4+ or CD8+ T cells was equal to or greater than two times the baseline value of IFN-γ. ICS
results are reported as the difference between the baseline and experimental IFN-γ values.
Humoral response to BKPyV
BKPyV pseudovirion-coated ELISA was used to quantify anti-BKPyV IgG against BKPyV
serotype I as has been previously described[26]. Results were reported as mean values of dupli-
cate reactions. The serum dilution in assays for anti-BKPyV IgG was 1:100. The cut-off for
seropositivity was an OD value >0.20.
T lymphocyte phenotyping
A 100μl aliquot of whole blood was stained with fluorescently-conjugated antibodies specific
for human CD3 (clone SP34.2 BD Biosciences), CD4 (clone L200 BD Biosciences), CD8 (clone
RPA-T8 BioLegend), CD45RO (clone UCHL1 Beckman Coulter), CD27 (clone M-T271 BD
Biosciences), CD38 (clone HB7 BD Biosciences), HLA-DR (clone L243 BD Biosciences), and
PD-1 (clone EH12.2H7 BioLegend). Samples were run through TQ-Prep machine (Beckman
Coulter) to lyse red blood cells, washed in D-PBS, and fixed in 1.5% formaldehyde. Data were
collected by running the samples through multicolor flow cytometry on a LSRII flow cytome-
ter (BD Biosciences), and analyzed with FlowJo software (Treestar Inc.) The gating strategy
was as follows:T-cells were identified by forward vs side scatter, excluded of doublets, and fur-
ther gated on CD3+ cells, which were then subdivided into CD3+/CD4+ and CD3+/CD8+ pop-
ulations. Those, in turn, were subdivided by receptor status into naïve cells (CD45RO-/
CD27+), effector cells (CD45RO-/CD27-), effector memory cells (CD45RO+/CD27-) and cen-
tral memory cells (CD45RO+/CD27+). Each subset was evaluated for expression of activation
markers CD38 and HLA-DR, and for exhaustion marker PD-1.
BKPyV DNA Detection
DNA extraction was performed with the QIAamp MinElute Virus Spin Kit (Qiagen, CA) fol-
lowing kit protocol. BKPyV DNA was quantified by Quantitative PCR (qPCR) using 7300 Real
Time PCR System (Applied Biosystems, CA). The primer pair 50-AGTGGATGGGCAGCCTA
TGTA-30 (nt 2511–2531) and 50-TCATATCTGGGTCCCCTGGA-30 (nt2586–2605), and probe
6FAM-AGGTAGAAGAGGTTAGGGTGTTTGATGGCACA-TAMRA(nt 2546–2578) (Applied Bio-
systems, CA), located in the VP1 gene, were used for qPCR detection, as previously described
[27], with a C to G modification of nucleotide 2569. For each serum or urine sample, the
extraction volume was 200μl and the elution volume was 150μl. Each qPCR reaction was run
in triplicate and all results were expressed in copies/ml.
Immune senescence and BK virus reactivation
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Data analysis
Categorical independent variables were compared using Fisher’s exact test and data are pre-
sented as number (N) and percent (%) of population. Continuous and ordinal independent
variables were compared using the Kruskal-Wallis test and data are presented as means and
standard deviations. Longitudinal variables were analyzed using linear or logistic generalized
estimating equations (GEE)[28] in order to control for intra-individual correlations intro-
duced by repeated measures. To identify variables associated with viremia and viruria, an
exploratory univariable logistic regression screen was utilized with an inclusion P value cut off
of 0.15[29] for multivariable analysis. A stepwise selection process starting with the candi-
date variable with the lowest P value was undertaken to identify variables for multivariable
analysis. Due to a low event number, a multivariable analysis for viremia as the outcome was
not performed, rather a combined outcome of viruria and viremia together was analyzed. Var-
iables were added in a step-wise fashion based upon their P value and retained in the model if
their P value was 0.10. This process proceeded until all variables had a P value0.10 or were
identified as significant confounding variables. Logistic regression data are presented as an
odds ratio with 95% CI and P value. All P values presented are two-tailed P values with
P< 0.05 considered statistically significant. Statistical analysis performed on Stata version 14
statistical software, StataCorp LP, College Station, Tx. Graphics performed on GraphPad
Prism Version 5.0 software, GraphPad Software, La Jolla CA.
Results
Patient characteristics and outcomes
29 patients were enrolled and 28 underwent transplantation. One transplant was canceled due
to donor complications. Patients were retrospectively stratified into groups with no viral reac-
tivation (BK Negative), viruria only and viremia. No significant differences were found in
recipient, donor or transplant characteristics between the 3 groups (Table 1). 7/28 (25%)
patients had BKPyV reactivation in either urine or blood by standard of care clinical screening.
Two additional patients were found to be viruric by research lab qPCR, making 9 (32%) total
reactivations. 6 (21%) developed viruria only and 3 (11%) developed viremia (Table 2). 1/29
(4%) patient was found to have viruria prior to transplant. 3 patients developed viruria within
the first month post-transplant and all reactivations occurred within 6 months. Viremia devel-
oped between 3 and 6 months in all 3 cases with peak viral loads of 27,022 copies/ml, 2,111
copies/ml and 19,031 copies/ml. There were no cases of sustained viremia or BKN in the study
period. All 3 viremic patients were treated with IS reduction and 2/3 (67%) were treated with
Leflunomide. 1/6 (17%) viruric patient was treated with IS reduction. Viremia patients had a
trend to higher serum creatinine at 12 months post-transplant at 1.60 (±0.26) mg/dL com-
pared to viruria patients at 1.22 (±0.41) mg/dL and BK negative at 1.31 (±0.30) mg/dL
(P = 0.20), but this did not attain statistical significance. There were 4 (14%) patients who
developed acute rejection, none of whom developed BKPyV reactivation.
BKPyV-specific T cell responses
Pre-transplant 20/21 (95%) tested patients had detectable CD4+ BKPyV-specific T-cells,
including 12/12 (100%) BK negative and 6/6 (100%) viruric patients, and 2/3 (67%) viremic
patients. All viruric and viremic patients developed CD4+ BKPyV-specific T-cells by 3 months
and maintained them through 12 months. Two BK negative patients transiently lost detectable
BKPyV-specific CD4+ T-cells post-transplant. 16/21 (76%) patients had CD8+ BKPyV-specific
T-cells at pre-transplant. All viremic patients and 5/6 (83%) viruric patients had BKPyV-
Immune senescence and BK virus reactivation
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Table 1. Study subject characteristics.
BK Viremia BK Viruria BK Negative P Value
Number of Patients 3 6 19
Recipient Age (Years) 45.71 (± 19.40) 54.68 (± 14.53) 51.3 (± 11.73) P = 0.72
Recipient Gender
Male 3 4 13
Female 0 2 6 P = 0.68
Recipient Race
Caucasian 2 5 18
African American 1 0 1
Asian 0 1 0 P = 0.18
Cause of Renal Disease
Diabetes 2 3 7
Primary GN 1 3 1
ADPKD 0 0 4
Obstruction/Pyelonephritis 0 0 3
Other 0 0 4 P = 0.21
On RRT at time of transplant
Yes 2 1 4
No 1 5 11 P = 0.29
Recipient CMV Serostatus
Positive 2 2 3
Negative 1 4 16 P = 0.11
Induction Immune Suppression
rATG 2 5 15
Basiliximab 1 1 2 P = 0.73
Corticosteroid Withdrawal
No 2 0 4
Yes 1 6 15 P = 0.10
Donor Age (Years) 58.20 (± 3.38) 43.54 (± 14.40) 45.06 (± 11.42) P = 0.14
Type of Transplant
LRRT 1 4 7
LURT 2 2 11
DDRT 0 0 1 P = 0.66
Donor Gender
Male 0 2 5
Female 3 4 14 P = 0.82
Donor Race
Caucasian 2 5 18
African American 1 0 0
Asian 0 1 0 P = 0.06
Warm Ischemia Time (min) 34.00 (± 9.86) 41.50 (± 15.80) 50.97 (± 30.43) P = 0.56
Cold Ischemia Time (min) 168.67 (± 243.66) 30.50 (± 12.22) 65.36 (±91.89) P = 0.26
Categorical variables were compared using Fisher’s exact test and data are presented as number (N). Continuous and ordinal independent variables were
compared using the Kruskal-Wallis test and data are presented as means and standard deviations. GN = glomerulonephritis; ADPKD = autosomal
dominant polycystic kidney disease; RRT = renal replacement therapy; rATG = rabbit anti-thymocyte globulin; LRRT = living related renal transplant;
LURT = living unrelated renal transplant; DDRT = deceased donor renal transplant.
https://doi.org/10.1371/journal.pone.0177339.t001
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specific CD8+ T-cells, but only 8/12 (67%) BK negative patients did. At 1 month post-trans-
plant, only 1/3 (33%) viremic patients had detectable CD8+ BKPyV-specific T-cells, while the
prevalence did not change in viruric or BK negative patients. By 3 months, all patients with
viral reactivations had CD8+ BKPyV-specific T-cells and maintained them through 12 months.
The prevalence of CD8+ BKPyV-specific T-cells in BK negative patients remained less
throughout the followup period at under 50%, though this did not reach statistical
significance.
The change in percent T-cells which were BKPyV-specific over time was evaluated utilizing
linear GEE regression (Table 3). BKPyV-specific CD4+ T-cells did not change in BK Negative
patients (0.10%/month; P = 0.64) or viruric patients (0.11%/month; P = 0.63) but significantly
increased in viremic patients (1.03%/month; P = 0.04). BKPyV-specific CD8+ T-cells increased
with time both in viremic patients (1.02%/month; P = 0.02), and viruric patients (0.51%/
month; P = 0.05). There was no significant change in BK negative patients (-0.03%/month;
P = 0.62). Utilizing Kruskal-Wallis to compare the percent CD4+ BKPyV-specific T-cells
between the three viral reactivation groups at each experimental time point, there was a non-
significant trend for higher counts in viremic patients (Fig 1A). The percent CD8+ BKPyV-
specific T-cells were higher in viremic (6.67±0.54) than viruric (1.54 ±1.21) and BK negative
(1.29 ±2.36) patients at 3 months (P = 0.02) post-transplant and, higher in viremic and viruric
patients than BK negative at 6 (BK negative 1.81 ±4.10, viruric 12.65 ±11.10 and viremic17.22
±18.68; P = 0.05) and 12 (BK negative 0.53 ±0.91, viruric 9.44 ±7.13, viremic 10.97 ±8.85;
P = 0.01) months post-transplant (Fig 1B).
T cell immuno-phenotype
CD4 and CD8 circulating T-cells were classified into their functional subtypes of central mem-
ory, effector memory, effector and naïve cells as described above (Fig 2A and 2B, S1 and S2
Tables). Viremic patients demonstrated a greater proportion of CD8+ T-cells with an effector
phenotype pre-transplant (21.41% ±13.11) compared to viruric (4.04% ± 4.51) and BK nega-
tive (5.49% ±4.76)(P = 0.04). This was also true at 12 months (viremic 14.49% ±3.76, viruric
3.86% ±1.65, BK negative 4.10% ±4.19, P = 0.01) (Fig 2B). No significant differences were
observed among the other CD8 subsets. Viremic patients demonstrated fewer CD4+ T-cells
with an effector memory subtype at 3 months post-transplant (5.59% ±2.32) compared to BK
negative (15.93% ±11.29) and viruric (20.00% ±12.00) (P = 0.05) (Fig 2A). No other significant
differences were observed among the other CD4 subsets.
Each of the subtypes of both CD4+ and CD8+ T-cells were analyzed for the expression of
activation markers CD38 and HLA-DR as well as the exhaustion marker PD-1. At one month
post-transplant, viremic patients were found to have fewer CD4+ central memory cells
Table 2. Prevalence of BKPyV detected in the plasma or urine.
Time Plasma Urine
Pre-Transplant 0/29 (0%) 1/29Ŧ (3%)
1 month 0/28 (0%) 3/28 (10.7%)
3 months 2/28 (7.1%) 4/28 (14.3%)
6 months 2/28 (7.1%) 5/28 (17.9%)
12 months 0/27 (0%) 2/27* (7.4%)
Ŧ: 1 patient’s transplant was canceled due to donor complications.
*: 1 patient received a pancreas after kidney transplant while viruric, he remained viruric only at 1 year, but is
not counted in our study after receiving the pancreas.
https://doi.org/10.1371/journal.pone.0177339.t002
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displaying the activation markers CD38 and HLA-DR. Fewer CD4+ central memory cells in
viremic patients expressed CD38 (38.04% ±15.90) compared to BK negative (57.10% ±12.01)
and viruric (60.07% ±14.67) (P = 0.04). Similarly, fewer CD4+ central memory cells in viremic
patients expressed HLA-DR (22.65% ±12.08), compared to viruric (39.33 ±7.42) and BK nega-
tive (33.84±7.77) (P = 0.03). There were no other significant differences among activation
markers found in any other subset. There were no significant differences among any subset
expressing exhaustion marker PD-1.
Anti-BKPyV IgG response
The humoral response to BK virus was assed via ELISA for IgG antibodies against the most
prevalent BK virus serotype in North America, BKPyV I[30]. Anti-BKPyV IgG was present
pre-transplant in 13/15 (87%) BK negative patients, 3/3 (100%) viremic and 5/6 (83%) viruric
patients. At 1 month post-transplant, 3/3 (100%) viremic, 5/5 (100%) viruric and 14/15 (93%)
BK negative patients had anti-BKPyV IgG.
Linear GEE regression demonstrated anti-BKPyV IgG increased with time for viruric
patients (0.08 units/month; P<0.01) and viremic patients (0.07 units/month; P <0.01), but did
not change in BK negative patients (0.01 units/month; P = 0.17) (Table 3). Utilizing the Krus-
kal-Wallis test, while the mean IgG against BKPyV was higher among viruric and viremic than
BK negative patients at 3, 6 and 12 months, this did not reach significance until month 12 (BK
negative 1.25 ± 0.70, viruria 2.03 ± 0.43, viremia 2.15 ± 0.02; P = 0.02) (Fig 3).
Table 3. GEE Linear regression for change in variable per month post-transplant.
BKV Reactivation Status Coefficient P Value Coefficient P Value Coefficient P Value
IFN-γ+ CD4 (% per month) IFN-γ+ CD8 (% per month) Anti BKV IgG (OD/month)
BK Negative 0.10 0.64 -0.03 0.62 0.01 0.17
Viruria 0.11 0.63 0.51 0.05 0.08 <0.01
Viremia 1.03 0.04 1.02 0.02 0.07 <0.01
OD = optical density, IFN-γ+ = interferon gamma positive
https://doi.org/10.1371/journal.pone.0177339.t003
Fig 1. BKPyV specific (A) CD4+ and (B) CD8+ T-cells. Line represents mean value. “-” = BK Negative, “U” = viruria, “P” =
viremia, “mo” = months post-transplant. “Pre-Tx” = Pre-transplant. P values were calculated by Kruskall-Wallis comparing all 3
groups at each time point. A: No significant difference at any time point. B: 3 month mean %IFN-γ producing CD8+ T-Cells for BK
negative 1.29 (±2.36), viruria 1.54 (±1.21), viremia 6.67 ±0.54), P = 0.02; 6 months mean for BK negative 1.81 (±4.10), viruria
12.65 (±11.10) and viremia 17.22 (±18.68), P = 0.05; 12 months mean for BK negative 0.53 (±0.91), viruria 9.44 (±7.13), viremia
10.97 (±8.85), P = 0.01.
https://doi.org/10.1371/journal.pone.0177339.g001
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Fig 2. Phenotypic composition of T lymphocytes in the BK negative, viruria, and viremia groups. 2A: CD4
+ T-Cell Phenotypes *P < 0.05. “Pre-Tx” = Pre-transplant. “mo” = Months post-transplant. P values were calculated by
Kruskall-Wallis comparing each T-cell subgroup at each time point. Effector Cells are CD45RO-/CD27-; Effector
Memory Cells are CD45RO+/CD27-; Central Memory Cells are CD45RO+/CD27+; Naïve Cells are CD45RO-/CD27+.
Expressed are means as a percent of total CD4+ T-Cells, may not add to 100% due to rounding. *Effector memory
cells at 3 months in BK negative 15.93% (±11.29), viruria 20.00% (±12.00) and viremia 5.59% (±2.32) P = 0.05. 2B:
Immune senescence and BK virus reactivation
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Factors associated with BKPyV reactivation
In an exploratory analysis, the clinical and experimental variables were screened utilizing GEE
logistic regression to evaluate their association with BKPyV reactivation, a combined endpoint
of viremia and viruria (Table 4). Of the baseline characteristics, the underlying reason for renal
failure was significantly associated with viral reactivation, with 4/5 (80%) patients with glomer-
ulonephritis (GN) and 5/12 (42%) patients with diabetes mellitus accounting for all viral reac-
tivations (P = 0.03). Of the experimental variables, several were significant predictors in
univariable analysis, including IgG titers against BKPyV, CD4+ and CD8+ BKPyV-specific T-
cells and CD4 and CD8 proportions. The multivariable analysis identified the cause of renal
failure (OR 0.44; 95% CI 0.19–0.99, P< 0.05), anti-BKPyV IgG (OR 4.01; 95% CI 1.54–10.46,
P<0.01), and percent of T-cells which are CD8+ (OR 1.04; 95% CI 1.00–1.07, P = 0.05) and
CD4+ (OR 0.95; 95% CI 0.92–0.98, P<0.01) as associated with viral reactivation. Immune sup-
pression and trough levels were not significant predictors.
Factors associated with BK viremia
A univariable screen was repeated to identify variables associated with BK viremia alone. In
the univariable screen, anti-BKPyV IgG (OR 3.16; 95% CI 1.05–9.48, P = 0.04), and CD4 (OR
CD8+ T-Cell Phenotypes *P < 0.05. “Pre-Tx” = Pre-transplant. “mo” = Months post-transplant. P values were
calculated by Kruskall-Wallis comparing each T-cell subgroup at each time point. Effector Cells are CD45RO-/CD27-;
Effector Memory Cells are CD45RO+/CD27-; Central Memory Cells are CD45RO+/CD27+; Naïve Cells are CD45RO-/
CD27+. Expressed are means as a percent of total CD8+ T-Cells, may not add to 100% due to rounding. *Baseline
percent effector cells for viremia is 21.41% (±13.11), viruria 4.04% (±4.51) and BK negative is 5.49% (±4.76), P = 0.04.
12 month percent effector cells for viremia is 14.49% (±3.76), viruria 3.86% (±1.64), and BK negative 4.10% (±4.19),
P = 0.01.
https://doi.org/10.1371/journal.pone.0177339.g002
Fig 3. Anti-BKPyV IgG. Line represents mean value. “OD” = Optical Density, “-” = BK Negative, “U” = viruria,
“P” = viremia, “mo” = months post-transplant. “Pre-Tx” = Pre-transplant. P values were calculated by Kruskall-
Wallis comparing all 3 groups at each time point. 12 month mean for BK negative 1.25 (± 0.70), viruria 2.03 (±
0.43), viremia 2.15(± 0.02), P = 0.02.
https://doi.org/10.1371/journal.pone.0177339.g003
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0.95; 95% CI 0.90–0.99, P = 0.02) and CD8 (OR 1.03; 95% CI 1.00–1.06, P = 0.05) proportions
were significantly associated with development of viremia (Table 5). No clinical characteristics
or immune suppression medications or troughs were significant predictors. A multivariable
model was not attempted due to the low number of viremia patients.
Discussion
BKN is an important and preventable cause of allograft dysfunction and loss. We have per-
formed a longitudinal analysis of the adaptive immune response to BKPyV reactivation,
including the timing and magnitude of the BKPyV-specific T-cell response in both CD4+ and
CD8+ cells and the humoral immune response. Additionally, we quantified T-cell phenotypes
to attempt to identify a profile which would be permissive of viral reactivation. Lastly, we eval-
uated these experimental factors alongside clinical data to fully assess risk of viral reactivation.
Previous work has demonstrated that a robust CD4+ T-cell response to viral capsid proteins
is associated with previously resolved BKPyV reactivation [24, 31–33], and an early post-trans-
plant CD8+ T-cell response[34], specifically polyfunctional CD8+ T-cells[35] is associated with
viral control. Our data demonstrate that the presence of CD4+ and CD8+ BKPyV-specific T-
cells is common in the pre-transplant population, and that the prevalence of BKPyV-specific
Table 4. GEE logistic regression for BKPyV reactivation.
Variable OR 95% CI P OR 95% CI P
Univariable Analysis Multivariable Analysis
Month 1.08 1.02–1.13 <0.01
MMF Dose 0.99 0.99–0.99 0.01
Recipient CMV Status 3.65 0.77–17.28 0.10
Recipient Race 0.31 0.07–1.48 0.14
Donor Race 0.19 0.02–1.53 0.12
Cause of Renal Failure 0.48 0.24–0.95 0.03 0.44 0.19–0.99 <0.05
Anti BKPyV IgG 3.98 1.77–8.93 <0.01 4.01 1.54–10.46 <0.01
Per % CD4 IFN-γ+ T-Cells 1.05 1.01–1.10 0.03
Per % CD8 IFN-γ+ T-Cells 1.08 1.01–1.15 0.03
Per % CD3+ T-Cells 0.98 0.97–1.00 0.03
Per % CD8+ T-Cells 1.04 1.01–1.06 <0.01 1.04 1.00–1.07 <0.05
Per % CD4+ T-Cells 0.94 0.91–0.96 <0.01 0.95 0.92–0.98 <0.01
OR = Odds Ratio. CI = Confidence Interval. Percent CD3+ T-Cells, CD4+ T-Cells and CD8+ T-Cells are the percent of peripheral blood mononuclear cells
(PBMC) which are CD3+ (T-Cells), CD4+ or CD8+ respectively. Percent CD4 IFN-γ+ and Percent CD8+ IFN-γ+ T-Cells are the percent of cultured PBMC
which secrete interferon gamma in response to BKPyV antigen stimulation. Cause of Renal Failure, see Table 1. MMF = mycophenolate mofetil.
https://doi.org/10.1371/journal.pone.0177339.t004
Table 5. Univariable GEE logistic regression for BKPyV viremia.
Variable OR 95% CI P
Univariable Analysis
Anti BKPyV IgG 3.16 1.05–9.48 0.04
Per % CD8+ T-Cells 1.03 1.00–1.06 0.05
Per % CD4+ T-Cells 0.95 0.90–0.99 0.02
OR = Odds Ratio. CI = Confidence Interval. Percent CD4+ T-Cells and Percent CD8+ T-Cells are the
percent of peripheral blood mononuclear cells (PBMC) which are CD3+ (T-Cells) and CD4+ or CD8
+ respectively.
https://doi.org/10.1371/journal.pone.0177339.t005
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T-cells drops immediately after transplant. Our data echoes prior studies which suggest the
absence of CD4+, CD8+, or both BKPyV-specific T-cells pre- and early post-transplant may be
a risk factor for viral reactivation[19]. We have shown an increase in both CD4+ and CD8+
BKPyV-specific T-cells in viremic patients and that this is associated with clearance of viremia
in all cases. Our data also show a significant, though less substantial, CD8+ BKPyV-specific T-
cell response in those with viruria, also associated with viral control. Our findings suggest a
role for monitoring the emergence of BKPyV-specific T-cells in those with BK reactivation
identified by screening. This would serve as a guide to identifying those with an adequate
response and likely, therefore, to have self-limited reactivation and in whom IS reduction is
unnecessary. Additionally, tracking BKPyV-specific T-cells could be used to guide the magni-
tude and monitor the effectiveness of step-wise IS reduction to prevent BKPyV progression
and prevent excess risk of allograft rejection.
Our data adds to prior clinical observations indicating that having experienced a humoral
response does not give full protection from post-transplant viral replication [24, 36]. It also
confirms the course of BKPyV-specific antibody response follows the level and duration of
BKPyV replication [22, 24, 25, 37]. By the first month post-transplant, all patients with viral
reactivation had positive anti-BKVPyV antibodies, and we demonstrated those titers increased
in viremic and viruric patients with time, but remained unchanged in BK negative patients.
We further evaluated circulating T lymphocytes by phenotype, which revealed several
important distinctions between the groups. The proportion of T-cells that are CD4+ was lower
and CD8+ T-cells were higher in viremic patients than viruric or BK negative patients before
transplant. Furthermore, a significantly greater proportion of CD8+ T-cells had a terminally
differentiated effector phenotype prior to transplant in viremic patients, a phenotype they
regained several months after transplant. Studies have identified an increased fraction of ter-
minally differentiated CD8+ T-cells along with low proportions of CD4+ and high proportions
of CD8+ T-cells as a marker of both age [38, 39] and uremia associated [40, 41] immune senes-
cence. Our results suggest that prior to ever receiving an immune suppressive regimen,
patients who later become viremic demonstrate a T-cell profile associated with immune
senescence.
Our analysis of clinical and experimental factors associated with BKPyV reactivation and
viremia identified markers of increased immune suppression, such as the presence of diabetes
mellitus or GN, conditions associated with immune dysfunction or immune dysregulation
[42–45], as the cause of renal failure, and of immune senescence, such as lower proportions of
CD4 T-cells and higher proportions of CD8 T-cells. They also include potential markers of
increased BKPyV burden, such as increased anti-BKPyV IgG titers.
Our exploratory analyses demonstrate lower CD4 and higher CD8 proportions were risk
factors for viremia and viruria and was also seen pre-transplant. CD4 T-cells are typically two-
fold higher than CD8 T-cells, and a drop in CD4/CD8 ratio has been associated with immune
senescence and mortality in elderly individuals [38]. This same profile has been described in
CKD patients irrespective of whether they are yet on RRT or RRT modality, and does not
improve post-transplant [40, 41, 46–48]. Immunologic aging and senescence are also associ-
ated with reduced naïve cells and expansion of terminally differentiated effector CD8+ T-cells
[48, 49], a feature which was also present in viremic patients in our analysis. This leads to esti-
mates that the adaptive immune system of ESRD patients is equivalent to healthy individuals
20–30 years older [46, 50]. Furthermore, these phenotypic changes seem to be driven or exac-
erbated by persistent CMV infection [38, 49]. The combination of low CD4/CD8 ratio and
CMV seropositivity has been identified as an “immunological risk profile” and recently shown
to predict severe bacterial infections and opportunistic infections after kidney transplant [51].
It has also been associated with a decreased risk of acute rejection [52]. Our study
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demonstrates for the first time in the literature that patients with features of an immune senes-
cence phenotype can be identified pre-transplant and that these persons may be at increased
risk of BKPyV reactivation. Additional clinical information, such as causes of renal failure
associated with immune suppression may further inform the risk profile.
Limitations of our study include a small number of patients, reducing the power of the
study to statistically identify all apparent differences. The small event number is particularly
important for our exploratory logistic analysis of risk factors for BKPyV reactivation and vire-
mia. The screening of large numbers of clinical and experimental variables for these analyses
increases the risk of type 1 error, and these analyses should be viewed as hypothesis generating.
Our patients were from two centers, utilizing mostly rATG and an early corticosteroid with-
drawal protocol, almost all from living donors and a high percentage were preemptive trans-
plants, potentially limiting generalizability. The frequency of BKPyV-specific T cells is low,
requiring ex-vivo stimulation to study, limiting the clinical applicability of this method, though
it is a common method used for study and is thought to represent the in vivo conditions[53].
Our longitudinal data were collected prospectively and reflect “real world” conditions of
screening and response to intervention; they also incorporate both experimental and clinical
data. Our study serves as a hypothesis generating pilot study, and results need to be replicated
in larger studies. Further research on larger numbers of patients, in patients with non-living
donors and in BKN patients is needed.
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